gubra.dkCrawled Nov 7, 2026
Gubra advances next-generation peptide therapeutics through drug discovery and partnerships.
Gubra provides MASH animal models with high clinical translatability and human proximity, ranked by LITMUS.
Spectra is Gubra Green’s solar and battery park in Denmark, supporting renewable energy and biodiversity.
Gubra’s R&D pipeline drives peptide-based therapeutics in metabolic, fibrotic, inflammatory, CNS, respiratory, and women’s health diseases.
The page examines trends in anti-obesity drug development from preclinical to clinical research.
The Gubra blog covers updates and analysis in preclinical and clinical research.
The page discusses the FDA approval of Madrigal’s Resmetirom, the first drug for MASH treatment.
Media Image Library
Gubra shares company news and corporate insights as a preclinical CRO services provider.
Career opportunities at Gubra
Audit Committee The Audit Committee consists of Alexander Thomas Martensen-Larsen as chair and Jacob Jelsing and Astrid Haug as ordinary members. The audit comm
Investor Relations Committees
Leadership team overview
Gubra’s mission combines science with purpose.
Sustainability initiatives at Gubra
Gubra integrates ESG into operations, innovation, and growth using a science-based, stakeholder-driven approach.
Gubra Green allocates 10% of the Group’s annual pre-tax profit to net-zero and nature-positive initiatives.
Investor Relations Contact
Gubra is specialized in high-end preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases.
Privacy Policy Data controller: Gubra A/S Hørsholm Kongevej 11B 2970 Hørsholm Denmark Dataprivacy@gubra.com GUBRA is subject to the General Data Protection Reg
Terms of use This website (“the Website”) provides corporate, investor-relations and other information seeking information about Gubra A/S, CVR no: 30514041, Hø
